Abstract of the preliminary data from this study was presented at the annual meeting of the “Österreichische Gesellschaft für Ophthalmologie” in May 2024.
Disclosure: K.L. Huber, None; H. Stino, None; I. Steiner, None; P. Fuchs, None; F. Goldbach, None; J. Mai, Apellis (C), Boehringer Ingelheim (C), Roche (C); B.S. Gerendas, Roche (C), Zeiss (C), Abbvie (C), Bayer (C); K. Kriechbaum, None; U. Schmidt-Erfurth, Apellis (C, F), AbbVie (C, F), Alcon (F), Bayer (C), Medscape (C), Allergan (C), Roche (C), Boehringer (C), Aviceda (C), Annexon (C), Topcon (C), Alkeus (C), Genentech (C), Kodiak(C), Novartis(C), RetInSight (C), Apellis Pharmaceuticals (C); A. Pollreisz, Allergan (C), Bayer (C), Roche (C), Oertli Instruments (C)